The European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) has recommended restricting the use of cilostazol-containing medicines after concluding in a review that their benefits only outweigh risk in a small patient set.
The EMA's announcement noted that cilostazol-containing drugs available in the EU include Otsuka Pharmaceutical's Pletal and Lacer's Ekistol. The drugs...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?